Arexvy is a vaccine used to protect against respiratory syncytial virus (RSV). RSV is a common virus that can lead to severe chest infections, pneumonia, and worsening of existing heart or lung conditions, particularly in older adults.
The vaccine is recommended for adults aged 60 years and over, and for those with underlying health conditions that increase the risk of severe RSV infection.
Vaccination course
-
Single dose injection
-
Provides protection for the RSV season
Booster doses
-
No routine booster is currently recommended
-
Future booster guidance may be updated based on ongoing recommendations
